XL147 analogue

N.º de catálogoS1118 Lote:S111802

Imprimir

Datos técnicos

Fórmula

C21H16N6O2S2
Peso molecular 448.52 Número CAS 956958-53-5
Solubilidad (25°C)* In vitro DMSO 89 mg/mL (198.43 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Agregue los solventes al producto individualmente y en orden.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml significa ligeramente soluble o insoluble.
* Tenga en cuenta que Selleck prueba la solubilidad de todos los compuestos internamente, y la solubilidad real puede diferir ligeramente de los valores publicados. Esto es normal y se debe a ligeras variaciones entre lotes.
* Envío a temperatura ambiente (Las pruebas de estabilidad demuestran que este producto se puede enviar sin medidas de refrigeración.)

Preparación de soluciones madre

Actividad biológica

Descripción El análogo de XL147 (SAR245408) es un inhibidor selectivo y reversible de la clase I de PI3K para PI3Kα/δ/γ con una IC50 de 39 nM/36 nM/23 nM en ensayos sin células, menos potente para PI3Kβ. Este compuesto induce apoptosis. Fase 1/2.
Objetivos
PI3Kγ
(Cell-free assay)		 PI3Kδ
(Cell-free assay)		 PI3Kα
(Cell-free assay)		 PI3Kβ
(Cell-free assay)
23 nM 36 nM 39 nM 383 nM
In vitro XL147 analogue inhibits class I PI3K isoforms in an ATP-competitive manner. In a panel of HER2-overexpressing human breast cancer cell lines, treatment with this compound abrogates AKT and S6 phosphorylation but also induces the expression and phosphorylation of HER3 and other RTKs. In HER2+ cells, phosphorylation of HER3 is maintained by the HER2 tyrosine kinase, leading to partial recovery of phosphorylated AKT (pAKT) and thereby limiting the antitumor action of this chemical. In addition, knockdown of HER3 or treatment with the anti-HER2 agents trastuzumab or lapatinib sensitizes HER2+ breast cancer cells to this agent in vitro and in vivo. Treatment with this inhibitor inhibits the monolayer growth of all tested cell lines, including BT474, HCC1937 et al. in a dose-dependent manner. The main effect of this compound is inhibition of cell proliferation. It induces cell death at the concentration of 20 μM. Treatment with this chemical leads to dose-dependent inhibition of PI3K. Consistent with the inhibition of cell proliferation, it induces a reduction in cyclin D1 and pRB and an increase in levels of the CDK inhibitor p27KIPI but no detectable change in levels off total or cleaved poly (ADP-ribose) polymerase (PARP). Treatment with this agent leads to a dose-dependent reduction in pAKTS473/T308 and pS6S240/244. Surprisingly, it also triggers up-regulation of total HER3 and/or pHER3Y1289 levels. In HER2-overexpressing cells, inhibition of PI3K is followed by up-regulation of expression and phosphorylation of multiple receptor tyrosine kinases, including HER3. Knockdown of FoxO1 and FoxO3a transcription factors prevents the induction of HER3, InsR, IGF1R, and FGFR2 mRNAs upon inhibition of PI3K. In HER2+ cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhances XL147-induced cell death and inhibition of pAKT and pS6.
In vivo Athymic mice with BT474 xenografts are randomly treated with XL147 analogue, lapatinib, trastuzumab, or this compound plus each HER2 antagonist. Each monotherapy significantly inhibtis tumor growth with trastuzumab being the only agent that induced a complete tumor regression in one of eight mice. Both combinations are superior to the respective drugs given alone. Notably, the combination of trastuzumab and this chemical, but not lapatinib and XL147, induces a complete tumor response in three of eight mice. There is no marked drug-related toxicity in any of the treatment arms. The combination of this compound plus trastuzumab prevents pHER3 more potently than any of the other treatments. In good agreement with differences in tumor growth among treatment arms, nuclear pAKT is lower in tumors treated with XL147 plus lapatinib or this chemical plus trastuzumab compared with tumors treated with single agents. Of all three single drugs, this compound is the only one shown statistically to repress nuclear pAKT levels. There are no detectable changes in cytoplasmic pAKT levels. Combined inhibition of HER2 and PI3K in HER2-dependent xenografts is required to maximally inhibit signaling output of the PI3K/AKT pathway.

Protocolo (de referencia)

Ensayo celular:

[2]
  • Líneas celulares

    BT474 and HCC1937 cells

  • Concentraciones

    0-20 μM

  • Tiempo de incubación

    72 hours

  • Método

    Cells including BT474, HCC1937 et al. are seeded in 100-mm dishes in media containing 2.5% FBS with or without this compound. After 3 days, detached and adherent cells are pooled, fixed, and labeled with propidium iodide by using the APO-BrdU kit. Labeled cells are analyzed using the Becton Dickinson FACSCalibur system.
Estudio en animales:

[2]
  • Modelos animales

    Athymic female mouse bearing BT474 cells

  • Dosificaciones

    100 mg/kg

  • Administración

    Orogastric gavage

Referencias

  • #
  • https://pubmed.ncbi.nlm.nih.gov/21368164/

Validación de productos por parte del cliente

<p>Breast cancer cells were pretreated with 100ng/ml EGF for 20 min and then treated with the indicated concentrations of XL147 for 24 hours.</p>

Dr. Zhang of Tianjin Medical University ,

<p>Western blot analysis of Akt and p-Akt. 0-15μM XL-147 was added.</p>

, , Dr. Chunrong Yu of RoswelI Park Cancer Institute

Selleck's XL147 analogue Ha sido citado por 18 Publicaciones

MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB [ Autophagy, June 15, 2012, 903-914] PubMed: 22576015
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB [ Autophagy, June 1, 2012, 903-914] PubMed: 22576015
Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo [ PLoS One, August 21, 2014, e105280] PubMed: 25144531
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258] PubMed: 35207746
Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome [ Hum Cell, 2022, 10.1007/s13577-022-00671-y] PubMed: 35118583
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ Journal of Personalized Medicine, 2022, 258] PubMed: 35207746
Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00579-z] PubMed: 34304386
Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone [ Hum Cell, 2021, 10.1007/s13577-021-00639-4] PubMed: 34731453
Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma [ Hum Cell, 2021, 34(6):1911-1918] PubMed: 34383271
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma [ Hum Cell, 2020, 10.1007/s13577-020-00420-z] PubMed: 32870449

POLÍTICA DE DEVOLUCIÓN
La Política de Devolución Incondicional de Selleck Chemical garantiza una experiencia de compra en línea fluida para nuestros clientes. Si no está satisfecho con su compra de alguna manera, puede devolver cualquier artículo(s) dentro de los 7 días posteriores a su recepción. En caso de problemas de calidad del producto, ya sean problemas relacionados con el protocolo o con el producto, puede devolver cualquier artículo(s) dentro de los 365 días a partir de la fecha de compra original. Siga las instrucciones a continuación al devolver productos.

ENVÍO Y ALMACENAMIENTO
Los productos Selleck se transportan a temperatura ambiente. Si recibe el producto a temperatura ambiente, tenga la seguridad de que el Departamento de Inspección de Calidad de Selleck ha realizado experimentos para verificar que la colocación a temperatura normal durante un mes no afectará la actividad biológica de los productos en polvo. Después de la recogida, guarde el producto de acuerdo con los requisitos descritos en la hoja de datos. La mayoría de los productos Selleck son estables en las condiciones recomendadas.

NO PARA USO HUMANO, DIAGNÓSTICO VETERINARIO O TERAPÉUTICO.